{"id":12715,"date":"2018-01-31T09:11:12","date_gmt":"2018-01-31T14:11:12","guid":{"rendered":"http:\/\/bioventuspub.wpengine.com\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/"},"modified":"2018-01-31T09:11:12","modified_gmt":"2018-01-31T14:11:12","slug":"additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m","status":"publish","type":"post","link":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/","title":{"rendered":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M"},"content":{"rendered":"<p><strong>KFAR SABA, ISRAEL and DURHAM, NC\u2013 January 31, 2018 &#8211;<\/strong> CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints, has secured a $2.5 million investment from Bioventus, a global leader in orthobiologics \u2013 reflecting the growing interest in CartiHeal\u2019s technology.<\/p>\n<p>Bioventus\u2019s $2.5 million boost complements CartiHeal\u2019s latest financing round, led by aMoon, together with Johnson &amp; Johnson Innovation (JJDC Inc.), Peregrine Ventures, and Elron, bringing the total round to $21 million.<\/p>\n<p>The funding will focus on CartiHeal\u2019s ongoing Agili-C IDE clinical study. Further to the trial&rsquo;s initiation three months ago, over thirty patients were already enrolled, according to enrollment rate forecasts.<\/p>\n<p>CartiHeal CEO, Nir Altschuler: \u201cThis investment is a vote of confidence by an important orthobiologic strategic player. Bioventus joins our team of strategic investors who perceived the potential of the Agili-C implant. We are confident that Bioventus will bring substantial added value to CartiHeal.\u201d<\/p>\n<p>\u201cAgili-C shows great promise to relieve osteoarthritis pain for a large patient population and we look forward following the pivotal trial to a successful culmination,\u201d said Tony Bihl, CEO, Bioventus.<\/p>\n<p><strong>About CartiHeal<\/strong><\/p>\n<p>CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.<\/p>\n<p><strong>About the Agili-C\u2122 implant IDE multinational pivotal study<\/strong><\/p>\n<p>The Agili-C\u2122 IDE study is set to include a minimum of 250 patients in US and OUS centers, aiming for a PMA submission. The trial&rsquo;s objective is to demonstrate the superiority of the Agili-C\u2122 implant over the surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both osteoarthritic knees and knees without degenerative changes.<\/p>\n<p><strong>About Bioventus<\/strong><\/p>\n<p>Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit <a href=\"https:\/\/new.bioventusglobal.com\">www.BioventusGlobal.com<\/a> and follow the company on Twitter <a href=\"https:\/\/twitter.com\/BioventusGlobal\">@Bioventusglobal.<\/a><\/p>\n<p>Bioventus and the Bioventus logo are registered trademarks of Bioventus, LLC.<\/p>\n<p>For Bioventus Contact: Thomas Hill, &nbsp;, <a href=\"mailto:thomashill@bioventusglobal.com\">thomas.hill@bioventusglobal.com<\/a><\/p>\n<p>For CartiHeal Contact: <a href=\"mailto:info@cartiheal.com\">info@cartiheal.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>KFAR SABA, ISRAEL and DURHAM, NC\u2013 January 31, 2018 &#8211; CartiHeal, developer of the proprietary Agili-C implant for the treatment [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-12715","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus\" \/>\n<meta property=\"og:description\" content=\"KFAR SABA, ISRAEL and DURHAM, NC\u2013 January 31, 2018 &#8211; CartiHeal, developer of the proprietary Agili-C implant for the treatment [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioventus\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-31T14:11:12+00:00\" \/>\n<meta name=\"author\" content=\"siteadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@siteadmin\" \/>\n<meta name=\"twitter:site\" content=\"@BioventusGlobal\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"siteadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/\"},\"author\":{\"name\":\"siteadmin\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#\\\/schema\\\/person\\\/d65c417397c1a3b1c45c0c12492aaae0\"},\"headline\":\"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M\",\"datePublished\":\"2018-01-31T14:11:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/\"},\"wordCount\":414,\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#organization\"},\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/\",\"url\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/\",\"name\":\"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-01-31T14:11:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/\",\"name\":\"Bioventus\",\"description\":\"Active Healing through Orthobiologics\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#organization\",\"name\":\"Bioventus\",\"url\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.bioventus.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/bioventus-logo-color-min.png\",\"contentUrl\":\"http:\\\/\\\/www.bioventus.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/bioventus-logo-color-min.png\",\"width\":434,\"height\":72,\"caption\":\"Bioventus\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/BioventusGlobal\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/bioventus\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/Bioventus\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.bioventus.com\\\/fr\\\/#\\\/schema\\\/person\\\/d65c417397c1a3b1c45c0c12492aaae0\",\"name\":\"siteadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g\",\"caption\":\"siteadmin\"},\"sameAs\":[\"https:\\\/\\\/www.bioventusglobal.com\",\"https:\\\/\\\/x.com\\\/siteadmin\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/","og_locale":"fr_FR","og_type":"article","og_title":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus","og_description":"KFAR SABA, ISRAEL and DURHAM, NC\u2013 January 31, 2018 &#8211; CartiHeal, developer of the proprietary Agili-C implant for the treatment [&hellip;]","og_url":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/","og_site_name":"Bioventus","article_published_time":"2018-01-31T14:11:12+00:00","author":"siteadmin","twitter_card":"summary_large_image","twitter_creator":"@siteadmin","twitter_site":"@BioventusGlobal","twitter_misc":{"\u00c9crit par":"siteadmin","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/#article","isPartOf":{"@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/"},"author":{"name":"siteadmin","@id":"https:\/\/www.bioventus.com\/fr\/#\/schema\/person\/d65c417397c1a3b1c45c0c12492aaae0"},"headline":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M","datePublished":"2018-01-31T14:11:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/"},"wordCount":414,"publisher":{"@id":"https:\/\/www.bioventus.com\/fr\/#organization"},"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/","url":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/","name":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M - Bioventus","isPartOf":{"@id":"https:\/\/www.bioventus.com\/fr\/#website"},"datePublished":"2018-01-31T14:11:12+00:00","breadcrumb":{"@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.bioventus.com\/fr\/additional-strategic-funding-cartiheals-ongoing-agili-c-ide-clinical-study-2-5m-boost-bioventus-brings-latest-investment-round-21m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bioventus.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Additional Strategic Funding for CartiHeal\u2019s Ongoing AGILI-C\u2122 IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M"}]},{"@type":"WebSite","@id":"https:\/\/www.bioventus.com\/fr\/#website","url":"https:\/\/www.bioventus.com\/fr\/","name":"Bioventus","description":"Active Healing through Orthobiologics","publisher":{"@id":"https:\/\/www.bioventus.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bioventus.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.bioventus.com\/fr\/#organization","name":"Bioventus","url":"https:\/\/www.bioventus.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.bioventus.com\/fr\/#\/schema\/logo\/image\/","url":"http:\/\/www.bioventus.com\/wp-content\/uploads\/2020\/04\/bioventus-logo-color-min.png","contentUrl":"http:\/\/www.bioventus.com\/wp-content\/uploads\/2020\/04\/bioventus-logo-color-min.png","width":434,"height":72,"caption":"Bioventus"},"image":{"@id":"https:\/\/www.bioventus.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/BioventusGlobal","https:\/\/www.linkedin.com\/company\/bioventus\/","https:\/\/www.youtube.com\/user\/Bioventus"]},{"@type":"Person","@id":"https:\/\/www.bioventus.com\/fr\/#\/schema\/person\/d65c417397c1a3b1c45c0c12492aaae0","name":"siteadmin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/267f86eb738c42e6434b931b776b69753eab05ef508f24c5a6c9e7baf46df621?s=96&d=mm&r=g","caption":"siteadmin"},"sameAs":["https:\/\/www.bioventusglobal.com","https:\/\/x.com\/siteadmin"]}]}},"_links":{"self":[{"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/posts\/12715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/comments?post=12715"}],"version-history":[{"count":0,"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/posts\/12715\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/media?parent=12715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/categories?post=12715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bioventus.com\/fr\/wp-json\/wp\/v2\/tags?post=12715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}